Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on February 5, 2014. The filing coincides with the closing of the Company's Initial Public Offering (IPO). The report details corporate governance changes and executive employment agreements executed in connection with the IPO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation structures.
Executive Compensation
| Executive Officer | Position | Base Salary | Target Bonus (% of Base) |
|---|---|---|---|
| Dr. Derek Chalmers | Chief Executive Officer | $440,000 | 50% |
| Dr. Frédérique Menzaghi | Vice President – Research and Development | $302,500 | 35% |
| Mr. Josef Schoell | Chief Financial Officer | $209,000 | 35% |
Material Changes
- Corporate Governance: The Company filed an Amended and Restated Certificate of Incorporation and Bylaws effective February 5, 2014.
- Capital Structure: Authorized 100,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock. All references to previously existing preferred stock were eliminated.
- Board Structure: The Board is now divided into three classes with staggered three-year terms. Directors may only be removed for cause with a two-thirds vote of outstanding shares.
- Shareholder Rights: Stockholders can no longer take action by written consent; special meetings may only be called by the Board, Chairman, or CEO.
- Executive Agreements: New employment agreements were executed for the CEO, VP of R&D, and CFO, including severance provisions for termination without cause or resignation for good reason (CEO only).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed relates to the new governance provisions, which restrict shareholder ability to remove directors or call special meetings, potentially limiting shareholder influence.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific anti-takeover provisions.
- Review the full Employment Agreements (Exhibits 10.1, 10.2, 10.3) to understand specific severance triggers and payment calculations.
- Confirm the final IPO share price and total capital raised, as this filing only references the closing of the IPO without stating the financial proceeds.
- Check subsequent filings for the actual issuance of the 5,000,000 authorized preferred shares.